Earnings Call
Apr 30, 2026
Q1 FY2026
EPS Estimate
0.90
EPS Actual
1.51
Post-Earnings Close
$309.49
Earnings Reaction
+2.8%
Alnylam crossed a meaningful commercial threshold in Q1 2026, generating over $1 billion in net product revenues for the first time in its history, a milestone that reflects the scale of the ATTR-CM opportunity and the pace at which AMVUTTRA has penetrated it. Total net product revenues of $1.036 billion represented 121% year-over-year growth and 4% sequential growth, with the TTR franchise accounting for $910 million of that figure. The rare disease portfolio contributed $126 million, up 15% year-over-year, providing a steady and consistent base. Combined with $82 million in collaboration revenue and $49 million in royalties, the latter up 85% year-over-year on the back of rising LEQVIO sales, total revenues came in well above the $1.1 billion consensus estimate, though the company did not report a specific GAAP or non-GAAP EPS figure on the call beyond confirming its third consecutive quarter of both GAAP and non-GAAP profitability.
Report generated on May 4, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full ALNY analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.